CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia
-
- Margaret L. Green
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA;
-
- Wendy M. Leisenring
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and
-
- Hu Xie
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and
-
- Roland B. Walter
- Department of Medicine, University of Washington, Seattle, WA;
-
- Marco Mielcarek
- Department of Medicine, University of Washington, Seattle, WA;
-
- Brenda M. Sandmaier
- Department of Medicine, University of Washington, Seattle, WA;
-
- Stanley R. Riddell
- Department of Medicine, University of Washington, Seattle, WA;
-
- Michael Boeckh
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA;
書誌事項
- 公開日
- 2013-08-15
- DOI
-
- 10.1182/blood-2013-02-487074
- 公開者
- American Society of Hematology
この論文をさがす
説明
<jats:title>Key Points</jats:title> <jats:p>CMV reactivation after HCT is associated with a reduced risk of early relapse in patients with AML but not other disease groups. The benefit, however, is offset by an increased risk of nonrelapse mortality.</jats:p>
収録刊行物
-
- Blood
-
Blood 122 (7), 1316-1324, 2013-08-15
American Society of Hematology